冠状动脉窦缩窄器治疗难治性心绞痛(ORBITA-COSMIC):一项随机安慰剂对照试验
ORBITA-COSMIC是一项在6家英国医院开展的双盲随机安慰剂对照试验,纳入61例(随机51例)有症状、稳定冠心病、存在缺血且无进一步治疗选择的患者,1:1随机接受冠状动脉窦缩窄器(CSR,n=25)或安慰剂(n=26),随访6个月。主要终点为腺苷负荷灌注心脏磁共振缺血节段心肌血流,CSR组与安慰剂组无差异(差值0.06 mL/min per g,95% CrI -0.09至0.20;Pr(Benefit)=78.8%)。主要症状终点每日心绞痛发作次数在CSR组减少(OR 1.40,95% CrI 1.08至1.83;Pr(Benefit)=99.4%)。CSR组发生2例CSR栓塞事件,两组均无急性冠脉综合征事件或死亡。
要点
- CSR与安慰剂相比未改善缺血节段心肌血流(差值0.06 mL/min per g,95% CrI -0.09至0.20;Pr(Benefit)=78.8%)。
- CSR与安慰剂相比减少每日心绞痛发作次数(OR 1.40,95% CrI 1.08至1.83;Pr(Benefit)=99.4%)。
- CSR组发生2例CSR栓塞事件,两组均无急性冠脉综合征事件或死亡。
- 适用人群为年龄≥18岁、有心绞痛、稳定冠心病、存在缺血且无进一步治疗选择的患者。
- 作者认为这些发现为CSR作为稳定冠心病患者的进一步抗心绞痛选择提供了证据。
适用人群与场景
- 年龄18岁或以上、有心绞痛、稳定冠心病、存在缺血且无进一步治疗选择的患者。
红旗征与不能漏的情况
- CSR组发生2例CSR栓塞事件。
研究设计与关键结果
- ORBITA-COSMIC为双盲、随机、安慰剂对照试验,在6家英国医院开展,2021年5月26日至2023年6月28日入组61例患者,51例随机(CSR组n=25,安慰剂组n=26;44例[86%]男性,7例[14%]女性),50例纳入意向性治疗分析(CSR组24例,安慰剂组26例)。
- 入组时800个成像心脏节段中454个(57%)为缺血,负荷心肌血流中位数为1.08 mL/min per g(IQR 0.77-1.41)。
- 缺血节段心肌血流CSR组与安慰剂组无差异(差值0.06 mL/min per g,95% CrI -0.09至0.20;Pr(Benefit)=78.8%)。
- 每日心绞痛发作次数CSR组较安慰剂组减少(OR 1.40,95% CrI 1.08至1.83;Pr(Benefit)=99.4%)。
- CSR组发生2例CSR栓塞事件,两组均无急性冠脉综合征事件或死亡。
证据类型、等级与局限
- 证据类型:双盲、随机、安慰剂对照试验。
对床旁实践的改变
- 作者认为,这些发现为CSR作为稳定冠心病患者的进一步抗心绞痛选择提供了证据。
- 在无进一步治疗选择的稳定冠心病患者中,CSR未改善缺血节段心肌血流,但减少每日心绞痛发作次数。
- 需注意CSR组发生2例CSR栓塞事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The coronary sinus reducer (CSR) is proposed to reduce angina in patients with stable coronary artery disease by improving myocardial perfusion. We aimed to measure its efficacy, compared with placebo, on myocardial ischaemia reduction and symptom improvement.
METHODS: ORBITA-COSMIC was a double-blind, randomised, placebo-controlled trial conducted at six UK hospitals. Patients aged 18 years or older with angina, stable coronary artery disease, ischaemia, and no further options for treatment were eligible. All patients completed a quantitative adenosine-stress perfusion cardiac magnetic resonance scan, symptom and quality-of-life questionnaires, and a treadmill exercise test before entering a 2-week symptom assessment phase, in which patients reported their angina symptoms using a smartphone application (ORBITA-app). Patients were randomly assigned (1:1) to receive either CSR or placebo. Both participants and investigators were masked to study assignment. After the CSR implantation or placebo procedure, patients entered a 6-month blinded follow-up phase in which they reported their daily symptoms in the ORBITA-app. At 6 months, all assessments were repeated. The primary outcome was myocardial blood flow in segments designated ischaemic at enrolment during the adenosine-stress perfusion cardiac magnetic resonance scan. The primary symptom outcome was the number of daily angina episodes. Analysis was done by intention-to-treat and followed Bayesian methodology. The study is registered with ClinicalTrials.gov, NCT04892537, and completed.
FINDINGS: Between May 26, 2021, and June 28, 2023, 61 patients were enrolled, of whom 51 (44 [86%] male; seven [14%] female) were randomly assigned to either the CSR group (n=25) or the placebo group (n=26). Of these, 50 patients were included in the intention-to-treat analysis (24 in the CSR group and 26 in the placebo group). 454 (57%) of 800 imaged cardiac segments were ischaemic at enrolment, with a median stress myocardial blood flow of 1·08 mL/min per g (IQR 0·77-1·41). Myocardial blood flow in ischaemic segments did not improve with CSR compared with placebo (difference 0·06 mL/min per g [95% CrI -0·09 to 0·20]; Pr(Benefit)=78·8%). The number of daily angina episodes was reduced with CSR compared with placebo (OR 1·40 [95% CrI 1·08 to 1·83]; Pr(Benefit)=99·4%). There were two CSR embolisation events in the CSR group, and no acute coronary syndrome events or deaths in either group.
INTERPRETATION: ORBITA-COSMIC found no evidence that the CSR improved transmural myocardial perfusion, but the CSR did improve angina compared with placebo. These findings provide evidence for the use of CSR as a further antianginal option for patients with stable coronary artery disease.
FUNDING: Medical Research Council, Imperial College Healthcare Charity, National Institute for Health and Care Research Imperial Biomedical Research Centre, St Mary's Coronary Flow Trust, British Heart Foundation.
参考来源
- Foley MJ, Rajkumar CA, Ahmed-Jushuf F, et al. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet. 2024. PMID: 38604209. doi:10.1016/S0140-6736(24)00256-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。